Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 3
2008 6
2009 2
2010 1
2012 3
2013 2
2014 1
2015 5
2016 3
2017 4
2018 7
2019 6
2020 7
2021 10
2022 13
2023 18
2024 13
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC, Cheah CY; International CNS Prophylaxis Study Group. Lewis KL, et al. J Clin Oncol. 2023 Dec 10;41(35):5376-5387. doi: 10.1200/JCO.23.00365. Epub 2023 Oct 5. J Clin Oncol. 2023. PMID: 37797284
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Talaulikar D, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E. Castillo JJ, et al. Among authors: talaulikar d. Lancet Haematol. 2020 Nov;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6. Lancet Haematol. 2020. PMID: 33091356 Review.
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT; GLOW Consortium. Binkley MS, et al. Among authors: talaulikar d. J Clin Oncol. 2024 Jul 1;42(19):2271-2280. doi: 10.1200/JCO.23.01655. Epub 2024 Mar 26. J Clin Oncol. 2024. PMID: 38531001
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Opat S, et al. Among authors: talaulikar d. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366 Free PMC article.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Free article. Clinical Trial.
Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome.
Pandey A, Shen C, Feng S, Enosi Tuipulotu D, Ngo C, Liu C, Kurera M, Mathur A, Venkataraman S, Zhang J, Talaulikar D, Song R, Wong JJ, Teoh N, Kaakoush NO, Man SM. Pandey A, et al. Among authors: talaulikar d. Sci Adv. 2024 Jan 26;10(4):eadh3409. doi: 10.1126/sciadv.adh3409. Epub 2024 Jan 26. Sci Adv. 2024. PMID: 38277448 Free PMC article.
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
Lewis CS, Joy G, Jensen P, Barraclough A, Franco N, Talaulikar D, Hawkes EA, El-Galaly TC, Villa D, Dickinson M, Seymour JF, Cheah CY. Lewis CS, et al. Among authors: talaulikar d. Br J Haematol. 2024 Aug;205(2):534-541. doi: 10.1111/bjh.19470. Epub 2024 Apr 17. Br J Haematol. 2024. PMID: 38632873
Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
Ng AP, Adams R, Tiong IS, Seymour L, Talaulikar D, Palfreyman E, Enjeti A, Tate C. Ng AP, et al. Among authors: talaulikar d. Pathology. 2024 Jun;56(4):459-467. doi: 10.1016/j.pathol.2024.02.002. Epub 2024 Mar 19. Pathology. 2024. PMID: 38580613 Review.
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Anderson MA, Bennett R, Badoux X, Best G, Chia N, Cochrane T, Cull G, Crassini K, Harrup R, Jackson S, Kuss B, Lasica M, Lew TE, Marlton P, Opat S, Palfreyman E, Polizzotto MN, Ratnasingam S, Seymour JF, Soosapilla A, Talaulikar D, Tam CS, Weinkove R, Wight J, Mulligan SP. Anderson MA, et al. Among authors: talaulikar d. Intern Med J. 2023 Sep;53(9):1678-1691. doi: 10.1111/imj.16207. Intern Med J. 2023. PMID: 37743239 Free article.
91 results